Penumbra, Inc.

PEN ·Healthcare, Medical Devices, United States

Net Cash Flow Breakdown

FY2025 FY2024 FY2023 FY2021 FY2019 FY2018 FY2017

Total Cash from Operations: $48.4M

Line Item	Value	% of Total
Capital Expenditures	$6.9M	14.3%
Business Acquisitions	$14.8M	30.5%
Other Financing	$7.1M	14.7%
Working Capital	$2.4M	4.9%
Net Cash Flow	$17.2M	35.6%